SEHK:1800
SEHK:1800Construction

Is China Communications Construction’s New Dividend Plan Signaling a Strategic Shift for SEHK:1800 Investors?

China Communications Construction Company Limited recently reported earnings for the nine months ended September 30, 2025, with revenue and net income decreasing to CNY 513.92 billion and CNY 13.65 billion respectively compared to the prior year. The company announced both an interim dividend and a plan to distribute 20% of its first-half net profit as cash dividends, reinforcing its focus on rewarding shareholders despite lower earnings. With a new dividend plan signaling commitment to cash...
SEHK:2419
SEHK:2419Food

Why Is Dekon Food and Agriculture Group (SEHK:2419) Seeking H Share Conversion Amid Shifting Pork Market Trends?

Dekon Food and Agriculture Group recently announced plans to convert its domestic shares into H shares, subject to regulatory approval from the China Securities Regulatory Commission and the Hong Kong Stock Exchange. The company also reported an increase in pig sales volume for October 2025, even as average selling prices for market hogs declined, providing insights into ongoing trends in the agriculture sector. We'll explore how the move to improve share liquidity through H share conversion...
SEHK:1672
SEHK:1672Biotechs

Ascletis Pharma (SEHK:1672): Evaluating Valuation After Promising Phase Ib Obesity Data and Pipeline Expansion

Ascletis Pharma (SEHK:1672) has captured attention after sharing new Phase Ib data for its ASC30 oral tablet and injection. The results demonstrated up to 7% placebo-adjusted mean body weight reduction and strong safety signals, with only mild gastrointestinal issues reported. See our latest analysis for Ascletis Pharma. Ascletis Pharma’s rapid progress in its clinical obesity programs has sparked a flurry of investor enthusiasm, helping fuel a 243.5% year-to-date share price return. While...
SEHK:1066
SEHK:1066Medical Equipment

What Shandong Weigao Group Medical Polymer (SEHK:1066)'s Third Quarter Revenue Growth Means For Shareholders

Shandong Weigao Group Medical Polymer Company Limited announced on November 3, 2025, that unaudited third quarter revenue reached approximately RMB 3.26 billion, a 2.6% year-on-year increase. This steady revenue growth offers an up-to-date indicator of market demand for the company's medical device portfolio across China and beyond. We'll explore how this sustained sales momentum contributes to Shandong Weigao Group Medical Polymer's investment narrative and operational outlook. These 13...
SEHK:285
SEHK:285Communications

3 Asian Stocks Estimated To Be Trading At Discounts Of Up To 30%

As global markets face fluctuations, with concerns about elevated valuations and economic uncertainties in major regions like the U.S. and Europe, Asia presents intriguing opportunities for investors seeking value. In this environment, identifying undervalued stocks—those trading below their intrinsic worth—can be a strategic approach to potentially benefit from market inefficiencies and capture future growth prospects.
SEHK:1478
SEHK:1478Electronic

Q Technology (SEHK:1478) Valuation: Assessing New Growth Momentum After Latest Sales Jump and India Exit

Q Technology (Group) (SEHK:1478) reported a year-on-year rise in October 2025 sales volumes for its camera and fingerprint modules, reflecting gains in mobile phone, IoT, and smart vehicle markets. The company also exited its Q Tech India stake. See our latest analysis for Q Technology (Group). Q Technology’s latest operational gains have added a shot of energy to its momentum story this year. Despite recent volatility, with a 1-day share price climb of 4.34% offsetting some of last week’s...
SEHK:489
SEHK:489Auto

Is Rising Sales and Widening Losses Altering the Investment Case For Dongfeng Motor Group (SEHK:489)?

Dongfeng Motor Group reported earnings for the nine months ended September 30, 2025, with sales reaching CNY 87,363.77 million and revenue at CNY 90,998.64 million, both up from the prior year, but net loss widening to CNY 1,881.82 million. This combination of rising revenue alongside a much larger net loss highlights ongoing operational challenges even as the company grows its top line. We'll explore how profit pressures amid sales growth are shaping Dongfeng Motor Group's investment...
SEHK:2157
SEHK:2157Biotechs

Lepu Biopharma (SEHK:2157): Valuation in Focus After Landmark EGFR-Targeted ADC Approval

Lepu Biopharma (SEHK:2157) just received conditional marketing approval from China's National Medical Products Administration for an innovative EGFR-targeted antibody-drug conjugate to treat recurrent or metastatic nasopharyngeal carcinoma. This milestone is expected to generate global attention and increased investor interest. See our latest analysis for Lepu Biopharma. Lepu Biopharma’s momentum has certainly kept investors on their toes this year. After surging to a 148% year-to-date share...